ICCC - Immucell Corp.
IEX Last Trade
3.74
-0.070 -1.872%
Share volume: 39,701
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.81
-0.07
-1.84%
Fundamental analysis
5%
Profitability
0%
Dept financing
11%
Liquidity
38%
Performance
1%
Performance
5 Days
1.63%
1 Month
-10.31%
3 Months
-14.22%
6 Months
-28.35%
1 Year
-17.80%
2 Year
-48.84%
Key data
Stock price
$3.74
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.50 - $5.64
52 WEEK CHANGE
-$0.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Michael Brigham
Region: US
Website: http://www.immucell.com/
Employees: 43
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.immucell.com/
Employees: 43
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
immucell corporation is a biotechnology company based out of portland maine. immucell's focus is to create scientifically-proven and practical products that result in a measurable economical impact on animal health and productivity in the dairy and beed industries.
Recent news